Search - tctmd.com

Displaying 81 - 100 of 154

Sort: Relevancy | Date

News Conference News EAS 2019

FH Patients Derive Biggest Absolute Benefit From Statin Therapy: 4S Analysis

Michael O'Riordan

June 03, 2019

News Conference News SCAI 2019

Cancer and CV Disease Care: What’s Known? What Lies Ahead for Cardio-Oncology?

Yael L. Maxwell

May 30, 2019

News Conference News EAS 2019

CHD Mortality Significantly Elevated in Patients With Severe FH

Michael O'Riordan

May 29, 2019

News Conference News EAS 2019

Clear CVD Risk Reduction With PCSK9 Inhibitors, but No Mortality Effect: Meta-analysis

Michael O'Riordan

May 28, 2019

News Daily News

Higher Risk of Intracranial Hemorrhage With Aspirin in Primary Prevention

Michael O'Riordan

May 20, 2019

News Conference News ACC 2019

New DECLARE-TIMI 58 Data Shine a Light on Diabetes Patients Most Likely to Benefit From Dapagliflozin

Shelley Wood

March 26, 2019

News Conference News ACC 2019

First Ticagrelor Reversal Agent Shows Quick Onset, Long Duration in Early Results

Yael L. Maxwell

March 25, 2019

News Daily News

The Case for Collateralization: CABG’s Mechanism for Survival in Stable CAD Underappreciated by Patients

L.A. McKeown

February 26, 2019

News Conference News AHA 2018

Methotrexate, an Anti-inflammatory, Fails to Lower Risk of Cardiovascular Events: CIRT

Michael O'Riordan

November 10, 2018

News Daily News

FDA Approves Rivaroxaban for CV Event Reduction in CAD and PAD Patients

Todd Neale

October 12, 2018

News Daily News

Genetic Risk Score Identifies Individuals at Heightened Risk of CAD and Other Diseases

Michael O'Riordan

August 16, 2018

News Daily News

Serial CTA Shines a Light on Statin Effects in Subclinical CAD

Yael L. Maxwell

June 15, 2018

News Daily News

ESC Consensus Statement Tackles Inflammation, Cholesterol Connection in a Post-CANTOS World

Caitlin E. Cox

May 16, 2018

News Daily News

‘High Index of Suspicion’ First Step in Successful Management of SCAD

Michael O'Riordan

February 27, 2018

News Daily News

Multivessel Disease Patients See Benefits of Long-term Ticagrelor: PEGASUS-TIMI 54 Analysis

Yael L. Maxwell

January 31, 2018

News Conference News AHA 2017

Low-Dose Rivaroxaban Plus Aspirin Lowers Some Costs in COMPASS, but Full Economic Impact Unclear

Todd Neale

November 14, 2017

News Features

COMPASS: All Signs Point to Big Impact in CAD and PAD, Experts Predict

Todd Neale

September 15, 2017

News Conference News ESC 2017

Women at High Cardiovascular Risk Unlikely to Get to Low LDL Targets

Michael O'Riordan

August 30, 2017

News Conference News ESC 2017

Ultra-Low LDL Levels? FOURIER Suggests Efficacy of Evolocumab

Michael O'Riordan

August 28, 2017

News Daily News

‘Remnant’ Cholesterol Linked With CVD Risk, Even When LDL Levels Are Low

Michael O'Riordan

August 01, 2017

Advertisement

FH Patients Derive Biggest Absolute Benefit From Statin Therapy: 4S Analysis

Cancer and CV Disease Care: What’s Known? What Lies Ahead for Cardio-Oncology?

CHD Mortality Significantly Elevated in Patients With Severe FH

Clear CVD Risk Reduction With PCSK9 Inhibitors, but No Mortality Effect: Meta-analysis

Higher Risk of Intracranial Hemorrhage With Aspirin in Primary Prevention

New DECLARE-TIMI 58 Data Shine a Light on Diabetes Patients Most Likely to Benefit From Dapagliflozin

First Ticagrelor Reversal Agent Shows Quick Onset, Long Duration in Early Results

The Case for Collateralization: CABG’s Mechanism for Survival in Stable CAD Underappreciated by Patients

Methotrexate, an Anti-inflammatory, Fails to Lower Risk of Cardiovascular Events: CIRT

FDA Approves Rivaroxaban for CV Event Reduction in CAD and PAD Patients

Genetic Risk Score Identifies Individuals at Heightened Risk of CAD and Other Diseases

Serial CTA Shines a Light on Statin Effects in Subclinical CAD

ESC Consensus Statement Tackles Inflammation, Cholesterol Connection in a Post-CANTOS World

‘High Index of Suspicion’ First Step in Successful Management of SCAD

Multivessel Disease Patients See Benefits of Long-term Ticagrelor: PEGASUS-TIMI 54 Analysis

Low-Dose Rivaroxaban Plus Aspirin Lowers Some Costs in COMPASS, but Full Economic Impact Unclear

COMPASS: All Signs Point to Big Impact in CAD and PAD, Experts Predict

Women at High Cardiovascular Risk Unlikely to Get to Low LDL Targets

Ultra-Low LDL Levels? FOURIER Suggests Efficacy of Evolocumab

‘Remnant’ Cholesterol Linked With CVD Risk, Even When LDL Levels Are Low

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content